ImmunoGen drug fails cancer study, shares slide 40 percent [Reuters]
ImmunoGen, Inc. (IMGN)
Last immunogen, inc. earnings: 5/1 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.immunogen.com/investor-relations
Company Research
Source: Reuters
ImmunoGen drug fails cancer study, shares slide 40 percent | Reuters 1 Min Read (Reuters) - U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday. When compared with chemotherapy, ImmunoGen’s mirvetuximab soravtansine did not significantly prevent the disease from worsening. While the drug was tested as a standalone treatment in this instance, ImmunoGen is also evaluating it in combination with other therapies, as well as developing other drugs for different forms of cancer. The company said it would examine the trial results further to evaluate the drug’s potential as a standalone treatment. ImmunoGen was in a “strong” financial position and would continue to develop its other cancer treatments, it added. Shares of the company were last down 46 percent at $2.17 in early trade. Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikuma
Show less
Read more
Impact Snapshot
Event Time:
IMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMGN alerts
High impacting ImmunoGen, Inc. news events
Weekly update
A roundup of the hottest topics
IMGN
News
- Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Immunogen Inc SVP & CHIEF BUSINESS OFFICER Stacy Coen Sells 4,583 Shares [Yahoo! Finance]Yahoo! Finance
- ImmunoGen, Inc. (NASDAQ: IMGN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- AbbVie Sees Signs of Post-Humira Growth in Positive 2024 Outlook [BNN Bloomberg (Canada)]BNN Bloomberg
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
IMGN
Earnings
- 11/2/23 - Beat
IMGN
Sec Filings
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- IMGN's page on the SEC website